Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.35 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.35 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | PRKACA | P17612 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28351488 | 0.98 | KDM4E (0.39) | KDM4ECCNA2CDK2CCNA1POLB | |
| SCHEMBL7522906 | 0.81 | PIM3 (0.41) | KDM4ECCNA2CDK2CCNA1POLB | |
| SCHEMBL20488091 | 0.81 | CCNA2 (0.39) | KDM4ECCNA2CDK2CCNA1POLB | |
| SCHEMBL4594309 | 0.80 | ALDH1A1 (0.40) | KDM4EPOLBLMNAHPGDALDH1A1 | |
| SCHEMBL15826456 | 0.79 | CCNA2 (0.38) | KDM4ECCNA2CDK2CCNA1POLB | |
| SCHEMBL8574213 | 0.75 | BAZ2B (0.50) | KDM4EPOLBLMNAHPGDALDH1A1 | |
| SCHEMBL17894319 | 0.75 | CCNA2 (0.35) | KDM4ECCNA2CDK2CCNA1LMNA | |
| SCHEMBL16833262 | 0.74 | MAPT (0.53) | KDM4EPOLBPKMALDH1A1GAA | |
| SCHEMBL22900489 | 0.72 | KMT2A (0.46) | KDM4EADORA2AADORA1ADORA3ALDH1A1 | |
| SCHEMBL29811979 | 0.72 | BAZ2B (0.43) | KDM4ECCNA2CDK2CCNA1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115515681-A | GPR52 modulator compounds | 赫普泰雅治疗有限公司 | 2022-12-23 | — | — | CN | claimed |
| US-20110230407-A1 | HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN DEMYELINATING DISEASES AND CENTRAL NERVOUS SYSTEM TRAUMA | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2011-09-22 | — | — | US | claimed |
| EP-4540255-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| EP-4540242-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT DEGRADE SWI/SNF-RELATED MATRIX-ASSOCIATED ACTIN-DEPENDENT REGULATOR OF CHROMATIN SUBFAMILY A | Plexium, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| EP-4540254-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-110603254-B | Substituted pyrazole compounds and methods of using the same for treating hyperproliferative diseases | 班塔姆制药有限责任公司 | 2024-04-12 | — | — | CN | disclosed |
| WO-2023244806-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT DEGRADE SWI/SNF-RELATED MATRIX-ASSOCIATED ACTIN-DEPENDENT REGULATOR OF CHROMATIN SUBFAMILY A | Plexium, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023244615-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023244604-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
| CN-115515681-A | GPR52 modulator compounds | 赫普泰雅治疗有限公司 | 2022-12-23 | — | — | CN | disclosed |
| CN-110769823-A | Methods of using substituted pyrazole and pyrrole compounds and treating hyperproliferative diseases | 班塔姆制药有限责任公司 | 2020-02-07 | — | — | CN | disclosed |
| CN-110603254-A | Substituted pyrazole compounds and methods of using the same for treating hyperproliferative diseases | 班塔姆制药有限责任公司 | 2019-12-20 | — | — | CN | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| CN-104519742-A | Compositions comprising biological control agents and pesticides | BAYER CROP SCIENCE AG | 2015-04-15 | — | — | CN | disclosed |
| EP-2303861-A1 | PYRIDINE COMPOUNDS | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | disclosed |
| US-7879898-B1 | treating a chronic obstructive pulmonary disease using modulators of HGF/SF activity; for example, 3-(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)-1-(4-chlorophenyl)prop-2-en-1-one; emphysema | ANGION BIOMEDICA CORP. (US) | 2011-02-01 | — | — | US | disclosed |
| WO-2009064422-A2 | HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN FIBROTIC CONNECTIVE TISSUE DISEASES | ANGION BIOMEDICA CORP. (US) | 2009-05-22 | — | — | WO | disclosed |
| CN-1993331-A | N- (1- (1-benzyl -4-phenyl-1h-imidazol-2-yl) -2,2-dymethylpropyl) benzamide derivatives and related compounds as kinesin spindle protein (ksp) inhibitors for the treatment of cancer | CHIRON CORP (US) | 2007-07-04 | — | — | CN | disclosed |
| EP-1355921-A2 | MODULATORS OF CELLULAR PROLIFERATION AND ANGIOGENESIS, METHODS FOR USE AND IDENTIFICATION THEREOF | North Shore-Long Island Jewish Health System (US) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002002593-A2 | MODULATORS OF CELLULAR PROLIFERATION AND ANGIOGENESIS, METHODS FOR USE AND IDENTIFICATION THEREOF | NORTH SHORE-LONG ISLAND JEWISH HEALTH SYSTEM (US) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230407-A1 | HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN DEMYELINATING DISEASES AND CENTRAL NERVOUS SYSTEM TRAUMA | HGF, HGFAC, HDGF | KDM4E 4833/4885CCNA2 3951/4885CDK2 3107/4885 |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | SPR, QDPR, SRR | KDM4E 2294/4885CCNA2 4589/4885CDK2 3561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.